Skip to main content

Main menu

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Other Publications
    • cbm

User menu

  • My alerts

Search

  • Advanced search
Cancer Biology & Medicine
  • Other Publications
    • cbm
  • My alerts
Cancer Biology & Medicine

Advanced Search

 

  • Home
  • About
    • About CBM
    • Editorial Board
    • Announcement
  • Articles
    • Ahead of print
    • Current Issue
    • Archive
    • Collections
    • Cover Story
  • For Authors
    • Instructions for Authors
    • Resources
    • Submit a Manuscript
  • For Reviewers
    • Become a Reviewer
    • Instructions for Reviewers
    • Resources
    • Outstanding Reviewer
  • Subscription
  • Alerts
    • Email Alerts
    • RSS Feeds
    • Table of Contents
  • Contact us
  • Follow cbm on Twitter
  • Visit cbm on Facebook
LetterLetter
Open Access

Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy

Shuyi Hu, Zipeng Wu, Yingying Dai, Xinhong Shi, Qin Hu, Caolu Liu, Yifei Zhu, Ruofan Yu, Jingwen Li, Ying Liu, Tianyi Liu, Lin Lu, Chengyun Yao, Bo Shen, Meiqi Shi, Cheng Chen, Xiaohua Wang and Guoren Zhou
Cancer Biology & Medicine December 2025, 22 (12) 1544-1552; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0393
Shuyi Hu
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zipeng Wu
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yingying Dai
2Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xinhong Shi
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qin Hu
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caolu Liu
2Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yifei Zhu
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruofan Yu
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingwen Li
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Liu
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tianyi Liu
2Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lin Lu
2Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chengyun Yao
2Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Shen
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Meiqi Shi
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheng Chen
2Department of Radiotherapy, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
3Peking University Cancer Hospital (Inner Mongolia Campus), Affiliated Cancer Hospital of Inner Mongolia Medical University, Hohhot 010020, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cheng Chen
  • For correspondence: zhouguoren888{at}163.com wangxiaohua{at}jszlyy.com.cn njmudoctor{at}163.com
Xiaohua Wang
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xiaohua Wang
  • For correspondence: zhouguoren888{at}163.com wangxiaohua{at}jszlyy.com.cn njmudoctor{at}163.com
Guoren Zhou
1Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing 210009, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Guoren Zhou
  • For correspondence: zhouguoren888{at}163.com wangxiaohua{at}jszlyy.com.cn njmudoctor{at}163.com
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

Article Information

vol. 22 no. 12 1544-1552
DOI 
https://doi.org/10.20892/j.issn.2095-3941.2025.0393
PubMed 
41369248

Published By 
Cancer Biology & Medicine
History 
  • Received August 28, 2025
  • Accepted November 3, 2025
  • Published online December 23, 2025.

Article Versions

  • previous version (December 10, 2025 - 05:26).
  • You are viewing the most recent version of this article.
Copyright & Usage 
Copyright: © 2025, The Authors This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License.

Author Information

Funding

  • National Natural Science Foundation of China

    82273162
  • Jiangsu Cancer Hospital Science and Technology Development Fund Project

    YSZD202409

This work was supported by grants from the National Natural Science Foundation of China (Grant No. 82273162) and Jiangsu Cancer Hospital Science and Technology Development Fund Project (Grant No. YSZD202409).

PreviousNext
Back to top

In this issue

Cancer Biology & Medicine: 22 (12)
Cancer Biology & Medicine
Vol. 22, Issue 12
15 Dec 2025
  • Table of Contents
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Cancer Biology & Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy
(Your Name) has sent you a message from Cancer Biology & Medicine
(Your Name) thought you would like to see the Cancer Biology & Medicine web site.
Citation Tools
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy
Shuyi Hu, Zipeng Wu, Yingying Dai, Xinhong Shi, Qin Hu, Caolu Liu, Yifei Zhu, Ruofan Yu, Jingwen Li, Ying Liu, Tianyi Liu, Lin Lu, Chengyun Yao, Bo Shen, Meiqi Shi, Cheng Chen, Xiaohua Wang, Guoren Zhou
Cancer Biology & Medicine Dec 2025, 22 (12) 1544-1552; DOI: 10.20892/j.issn.2095-3941.2025.0393

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy
Shuyi Hu, Zipeng Wu, Yingying Dai, Xinhong Shi, Qin Hu, Caolu Liu, Yifei Zhu, Ruofan Yu, Jingwen Li, Ying Liu, Tianyi Liu, Lin Lu, Chengyun Yao, Bo Shen, Meiqi Shi, Cheng Chen, Xiaohua Wang, Guoren Zhou
Cancer Biology & Medicine Dec 2025, 22 (12) 1544-1552; DOI: 10.20892/j.issn.2095-3941.2025.0393
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Supporting Information
    • Conflict of interest statement
    • Author contributions
    • Data availability statement
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Identification of immune reconstitution and hematopoiesis restoration by scRNA-seq in bone marrow of multiple myeloma patients treated with high-dose melphalan following auto-HSCT
  • Blood-based prediction and early detection of pancreatic cancer recurrence after tumor resection
  • Impact of pre-neoadjuvant radioactive iodine seed marking on pathologic complete response and survival in early-stage breast cancer patients
Show more Letter

Similar Articles

Navigate

  • Home
  • Current Issue

More Information

  • About CBM
  • About CACA
  • About TMUCIH
  • Editorial Board
  • Subscription

For Authors

  • Instructions for authors
  • Journal Policies
  • Submit a Manuscript

Journal Services

  • Email Alerts
  • Facebook
  • RSS Feeds
  • Twitter

 

© 2026 Cancer Biology & Medicine

Powered by HighWire